TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8257887

Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg/day
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg/day
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Zidovudine early treatment
Number of subjects: 338
Study: 3899005

Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 40

Group type: COMPARATOR
Intervention: ticarcillin and tobramycin
Number of subjects: 40
Study: 31398997

Group type: EXPERIMENTAL
Intervention: 200 mg of dry extract of ginger (5% active ingredient) three times per day for three months
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (cellulose) three times per day for three months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both ginger and placebo
Number of subjects: 107
Study: 29524509

Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study: 26961775

Group type: EXPERIMENTAL
Intervention: 2MWT
Number of subjects: 26

Group type: COMPARATOR
Intervention: 6MWT
Number of subjects: 26
Study: 25457929

Group type: EXPERIMENTAL
Intervention: Medication management plus instructions in cognitive-behavioral therapy (CBT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Medication management plus full CBT
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication management
Number of subjects: 124
Study: 22955172

Group type: EXPERIMENTAL
Intervention: Lenalidomide (single doses of 5-400 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lenalidomide with high-fat meal
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lenalidomide without regard to food
Number of subjects: 58
Study: 20452305

Group type: EXPERIMENTAL
Intervention: Lumbar lordosis brace
Number of subjects: 11

Group type: COMPARATOR
Intervention: No lumbar lordosis brace
Number of subjects: 11
Study: 18076267

Group type: EXPERIMENTAL
Intervention: 24 hours of sleep loss
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 9
Study: 16101369

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioabsorbable membrane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 18
Study: 12435003

Group type: EXPERIMENTAL
Intervention: Various disinfecting solutions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no disinfecting solution)
Number of subjects: 32
Study: 10074977

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 194

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 194
Study: 9987734

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) with hMG/hCG and DIPI
Number of subjects: 65

Group type: COMPARATOR
Intervention: hMG/hCG without GnRHa
Number of subjects: 65
Study: 1807428

Group type: EXPERIMENTAL
Intervention: Health education intervention delivered by nurses on diet and health
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 88
Study: 6853264

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) administered orally at a dose of 3.0g/m2 and intravesically at a dose of 1.0g
Number of subjects: 22

Group type: COMPARATOR
Intervention: Historical controls (retrospective study)
Number of subjects: 22
Study: 31533845

Group type: EXPERIMENTAL
Intervention: Intervention (IPT with dihydroartemisinin-piperaquine)
Number of subjects: 10079

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10079
Study: 29796786

Group type: EXPERIMENTAL
Intervention: Missed opportunities for HIV testing
Number of subjects: 5012

Group type: EXPERIMENTAL
Intervention: Traditional testing settings
Number of subjects: 5012

Group type: EXPERIMENTAL
Intervention: Non-traditional testing settings
Number of subjects: 5012

Group type: EXPERIMENTAL
Intervention: Participants positive for HIV at baseline
Number of subjects: 5012
Study: 26955859

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14171

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Multiple characteristics (decreasing creatinine clearance, COPD, male sex, peripheral vascular disease, diabetes)
Number of subjects: 14171
Study: 25533338

Group type: EXPERIMENTAL
Intervention: Blackmores® Executive B Stress Formula
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 22260826

Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral solution (group II)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Standard enteral solution (group III)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Parenteral solution (group IV)
Number of subjects: 75
Study: 20605499

Group type: EXPERIMENTAL
Intervention: 80 mg/d soy isoflavones
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 120 mg/d soy isoflavones
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 18653341

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16479219

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenic protein-2 (rhBMP-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic analysis of rhBMP-2
Number of subjects: 0
Study: 12365323

Group type: EXPERIMENTAL
Intervention: Omeprazole, fromilid (clarithromycin), and metronidazole for 7 days followed by omeprazole for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omeprazole, fromilid (clarithromycin), and furazolidone for 7 days followed by omeprazole for 2 weeks
Number of subjects: 20
Study: 10872363

Group type: EXPERIMENTAL
Intervention: Closed-wedge high tibial osteotomy (HTO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open-wedge procedure based on the hemicallotasis technique (HCO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clinical results evaluated on Hospital for Special Surgery, Lysholm and Wallgren‐Tegner activity scores
Number of subjects: 46
Study: 8950072

Group type: EXPERIMENTAL
Intervention: LDL apheresis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normocholesterolemic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated hypercholesterolemic patients
Number of subjects: 0
Study: 1757613

Group type: EXPERIMENTAL
Intervention: Halobetasol propionate 0.05% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 6753643

Group type: EXPERIMENTAL
Intervention: Midazolam, 0.07 mg/kg (group M, 31 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 1.0 mg/kg (group H, 34 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam diluent as a placebo (group P, 35 patients)
Number of subjects: 100
Study: 31306077

Group type: EXPERIMENTAL
Intervention: Maxillary incisor intrusion arch
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flat anterior bite plate
Number of subjects: 32
Study: 28732480

Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26368559

Group type: EXPERIMENTAL
Intervention: Female infants
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Women pregnant with female fetuses
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Female fetuses
Number of subjects: 582
Study: 24120713

Group type: EXPERIMENTAL
Intervention: 4 × 100 μg FPNS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 × 400 μg FPNS
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 × 100 μg FPNS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 × 100 μg FPNS and 1 × 400 μg FPNS
Number of subjects: 20

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 20
Study: 21283921

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream (two-week cycle)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream (two-week cycle)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream (three-week cycle)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream (three-week cycle)
Number of subjects: 121
Study: 19042940

Group type: EXPERIMENTAL
Intervention: Cranberry extract (500 mg)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Trimethoprim (100 mg)
Number of subjects: 137
Study: 18001442

Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Oral clindamycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Metronidazole vaginal suppositories
Number of subjects: 156
Study: 15449205

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 0
Study: 11581566

Group type: EXPERIMENTAL
Intervention: Exercise training regimens differing in dose (kcal.wk‐1) and/or intensity (relative to peak VO2)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 384
Study: 9822463

Group type: EXPERIMENTAL
Intervention: Laparoscopic oophorectomy
Number of subjects: 25
Study: 7926102

Group type: EXPERIMENTAL
Intervention: Intra-amniotic methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO2 laser laparoscopic salpingotomy
Number of subjects: 0
Study: 2340210

Group type: EXPERIMENTAL
Intervention: Verapamil (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7404209

Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular ketamine and hyaluronidase
Number of subjects: 0
Study: 31915163

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Single-dose cephalosporin
Number of subjects: 220
Study: 30252088

Group type: EXPERIMENTAL
Intervention: Self-perceived character strengths
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Perception of leaders' character strengths
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Alignment with Australian Army core values
Number of subjects: 171
Study: 28674125

Group type: EXPERIMENTAL
Intervention: Guided self-determination group training (GSD-GT)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Care as usual (Control Group)
Number of subjects: 178
Study: 25766118

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab with 75% cost reduction
Number of subjects: 0
Study: 23391851

Group type: EXPERIMENTAL
Intervention: Combined intervention (parent and student intervention)
Number of subjects: 3490

Group type: COMPARATOR
Intervention: Parent intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: Student intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3490
Study: 21184975

Group type: EXPERIMENTAL
Intervention: Atkins diet (n=70)
Number of subjects: 311
Study: 19291119

Group type: EXPERIMENTAL
Intervention: Intralesional injections of 75 microg of Heberprot‐P three times per week up to complete wound healing
Number of subjects: 20
Study: 17522570

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) followed by intravenous NTG (up to 80 microg/min)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo followed by intravenous NTG (up to 160 microg/min)
Number of subjects: 34
Study: 15056579

Group type: EXPERIMENTAL
Intervention: Olanzapine plus mood stabiliser (lithium or valproate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mood stabiliser alone (lithium or valproate)
Number of subjects: 0
Study: 11788176

Group type: EXPERIMENTAL
Intervention: Oral therapy (continuous conjugated equine estrogens (CEE) ‐ 0.625mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transdermal therapy (patches delivering continuous 17beta‐estradiol (E2)‐‐0.05mg per day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (oral CEE and transdermal E2)
Number of subjects: 40
Study: 9711425

Group type: EXPERIMENTAL
Intervention: Burn patients on day 1
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Burn patients on day 3
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Burn patients on day 14
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Burn patients on day 21
Number of subjects: 134

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trauma patients on day of admission
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trauma patients on day 3
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trauma patients on day 7
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trauma patients on day 14
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trauma patients on day 21
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Uncomplicated healing patients (both burn and trauma)
Number of subjects: 134
Study: 7989945

Group type: COMPARATOR
Intervention: FAM (fluorouracil, doxorubicin, and mitomycin)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PELF (cisplatin, epirubicin, and leucovorin preceding fluorouracil)
Number of subjects: 130

Group type: COMPARATOR
Intervention: FAM
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PELF
Number of subjects: 130
Study: 2731120

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 5‐Fluorouracil, and prednisone (CFP)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: CFP, methotrexate, and vincristine (CFPMV)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: ER- patients
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: ER+ patients
Number of subjects: 182
Study: 55532

Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol
Number of subjects: 15
Study: 31286818

Group type: EXPERIMENTAL
Intervention: Internet drinkers (N=39)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Non-drinking counterparts (N=39)
Number of subjects: 550
Study: 29151313

Group type: EXPERIMENTAL
Intervention: 10 physical therapy sessions (Group 10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 physical therapy sessions (Group 15)
Number of subjects: 60
Study: 25560809

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Number of subjects: 422

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 422
Study: 23610200

Group type: EXPERIMENTAL
Intervention: Early review and use of cough algorithm (early-arm)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care until review and use of cough algorithm (delayed-arm)
Number of subjects: 272
Study: 20716625

Group type: EXPERIMENTAL
Intervention: Internet SCA
Number of subjects: 122

Group type: COMPARATOR
Intervention: Paper SCA
Number of subjects: 122
Study: 19776222

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 158
Study: 16741298

Group type: EXPERIMENTAL
Intervention: (18)F-FDOPA PET
Number of subjects: 81

Group type: COMPARATOR
Intervention: (18)F-FDG PET
Number of subjects: 81
Study: 15584808

Group type: EXPERIMENTAL
Intervention: Practiced high-demand problems (practiced 50 times)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequently practiced high-demand problems (practiced 1 or 2 times)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-pressure test on practiced problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpracticed problems with heavy working memory demands
Number of subjects: 0
Study: 11331718

Group type: EXPERIMENTAL
Intervention: 3-hour workshop on violence prevention (intervention group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard ambulatory clinic manual with articles on violence prevention (control group)
Number of subjects: 56
Study: 9014954

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) during rehabilitation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional rehabilitation services
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 28
Study: 8302446

Group type: EXPERIMENTAL
Intervention: Ventilated with O2 = 4 1/min‐1 and N2O = 6 1/min‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ventilated with O2 = 350 ml/min‐1 and N2O = 250 ml/min‐1, reducing N2O flow to keep FIO2 = 0.4
Number of subjects: 24
Study: 3574803

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: cefoxitin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: clindamycin plus gentamicin
Number of subjects: 152
Study: 30120069

Group type: EXPERIMENTAL
Intervention: Adjuvanted NmCV-5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted NmCV-5
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Menactra)
Number of subjects: 60
Study: 26980389

Group type: EXPERIMENTAL
Intervention: Nasal douches based on high concentration (9 mg) and high-molecular-weight sodium hyaluronate (active treatment group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nasal saline solution irrigation (control group)
Number of subjects: 94
Study: 25873781

Group type: EXPERIMENTAL
Intervention: Atrial Preference Pacing ON
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atrial Preference Pacing OFF
Number of subjects: 50
Study: 22327499

Group type: EXPERIMENTAL
Intervention: HAV vaccine (0, 6 month schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAV vaccine (0, 12 month schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAV challenge dose
Number of subjects: 0
Study: 20800922

Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alfa 2b and ribavirin for 48 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HLA class I alleles
Number of subjects: 159
Study: 18278501

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 63
Study: 15917152

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (60mg per day for 12 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract with PUFA supplement (two capsules per day for 24 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (two capsules per day for 12 weeks)
Number of subjects: 57
Study: 12650788

Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy (OBMT) with omeprazole, bismuth biskalcitrate 140 mg, metronidazole 125 mg, and tetracycline 125 mg for 10 days.
Number of subjects: 275

Group type: COMPARATOR
Intervention: Triple therapy (OAC) with omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg for 10 days.
Number of subjects: 275
Study: 10817585

Group type: EXPERIMENTAL
Intervention: Genotyping and linkage analysis of alpha2-macroglobulin genetic markers (A2MI and A2M2) in Japanese AD patients
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Genotyping and linkage analysis of alpha2-macroglobulin genetic markers (A2MI and A2M2) in Caucasian AD patients
Number of subjects: 426

Group type: COMPARATOR
Intervention: Comparison of genotype and allele frequencies in cognitively normal controls
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 426
Study: 8646868

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate ointment, 0.005%
Number of subjects: 113

Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate ointment, 0.1%
Number of subjects: 113
Study: 1996888

Group type: EXPERIMENTAL
Intervention: Screened group (58 infants)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Clinically diagnosed group (44 children)
Number of subjects: 102
Study: 6373152

Group type: EXPERIMENTAL
Intervention: 1200 mg oxaprozin once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 250 mg naproxen 3-times daily
Number of subjects: 24
Study: 30852374

Group type: EXPERIMENTAL
Intervention: XR‐NTX plus Abstinence Incentives
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: XR‐NTX
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Abstinence Incentives
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 84
Study: 30558933

Group type: EXPERIMENTAL
Intervention: Active vacuum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inactive vacuum
Number of subjects: 12
Study: 27248336

Group type: EXPERIMENTAL
Intervention: Navigated-TLIF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional-TLIF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 25027339

Group type: EXPERIMENTAL
Intervention: Cefoselis
Number of subjects: 276

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 276
Study: 22251483

Group type: EXPERIMENTAL
Intervention: Cytokine-based immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytokine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topically applied immunomodulatory treatment
Number of subjects: 0
Study: 20705755

Group type: EXPERIMENTAL
Intervention: As(2)O(3) consolidation
Number of subjects: 481

Group type: COMPARATOR
Intervention: Standard induction and consolidation therapy
Number of subjects: 481
Study: 17620446

Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 30 min after dosing (EX30)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 120 min after dosing (EX120)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 240 min after dosing (EX240)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No exercise (NOEX group)
Number of subjects: 23
Study: 16332666

Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg) plus vitamin B‐12 (500 microg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Vitamin B‐6 (25 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Riboflavin (25 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control (no folic acid plus vitamin B‐12)
Number of subjects: 185
Study: 11976239

Group type: EXPERIMENTAL
Intervention: Non-invasive H pylori test
Number of subjects: 708

Group type: COMPARATOR
Intervention: Endoscopy plus H pylori testing
Number of subjects: 708
Study: 9477931

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham depletion (control)
Number of subjects: 30
Study: 8583673

Group type: EXPERIMENTAL
Intervention: Midazolam syrup
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bromazepam suppository
Number of subjects: 77